CITIUS PHARMACEUTICALS
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.
CITIUS PHARMACEUTICALS
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
2007-01-01
Address:
Cranford, New Jersey, United States
Country:
United States
Website Url:
http://www.citiuspharma.com
Total Employee:
11+
Status:
Active
Contact:
(908)967-6677
Email Addresses:
[email protected]
Total Funding:
144.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Domain Not Resolving
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-04-04 | Leonard-Meron Biosciences | Leonard-Meron Biosciences acquired by Citius Pharmaceuticals | N/A |
Investors List
Leonard Mazur
Leonard Mazur investment in Post-IPO Equity - Citius Pharmaceuticals
Myron Holubiak
Myron Holubiak investment in Post-IPO Equity - Citius Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-05 | Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls |
Official Site Inspections
http://www.citiuspharma.com Semrush global rank: 2.51 M Semrush visits lastest month: 7.02 K
Unable to get host informations!!!
More informations about "Citius Pharmaceuticals"
Citius Pharmaceuticals, Inc. - About
Contact Us Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 908-967-6677 [email protected]See details»
Citius Pharmaceuticals - Crunchbase Company Profile & Funding
Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutic products.See details»
Citius Pharmaceuticals, Inc. | LinkedIn
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a …See details»
Citius Pharmaceuticals Announces Nomination of Pharmaceutical …
Jan 23, 2024 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first …See details»
Citius Pharmaceuticals - VentureRadar
"Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.See details»
Citius Pharmaceuticals Announces Key Management Realignment …
Apr 13, 2022 With a planned BLA submission for I/ONTAK later this year, along with the expected completion of enrollment in the Mino-Lok® trial in 2022, now is the ideal time to …See details»
Citius Pharmaceuticals, Inc. - About - Overview
Unlocking Potential. Faster. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in …See details»
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 ...
Aug 12, 2024 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization …See details»
Citius Pharma - Overview, News & Similar companies
View Citius Pharma (www.citiuspharma.com) location in New Jersey, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Citius Pharmaceuticals Details Near-Term Milestones for Late …
Jul 10, 2024 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first …See details»
Citius Pharmaceuticals Announces Closing of $15 Million …
Apr 30, 2024 In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit …See details»
About - Board of Directors - Person Details - Citius Pharma
Kelly joined Citius from Clinipace Worldwide, a leading global contract research organization, where he served as Vice President of Regulatory and Strategic Development. As a senior …See details»
Citius Pharmaceuticals Executes Definitive Agreement to Merge …
Oct 24, 2023 Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post …See details»
Citius’ first FDA decision date is approaching - PharmaVoice
Jul 26, 2024 Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.See details»
Citius Pharmaceuticals, Inc. - About - Board of Directors
Dec 31, 2023 Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns …See details»
Citius Pharma - PitchBook
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four …See details»
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints …
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in …See details»
Citius Pharmaceuticals, Inc. - Investors - Investment Highlights
Why Invest? FDA approved biologic for the treatment of cutaneous T-cell lymphoma Diversified pipeline of potential first-in-class products with multiple near-term staged catalysts Attractive …See details»
Citius Pharmaceuticals, Inc. - Investors - Financials & SEC Filings ...
By providing your email address below, you are providing consent to Citius Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.See details»